deferiprone has been researched along with HIV Coinfection in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saxena, D | 1 |
| Spino, M | 1 |
| Tricta, F | 1 |
| Connelly, J | 1 |
| Cracchiolo, BM | 1 |
| Hanauske, AR | 1 |
| D'Alliessi Gandolfi, D | 1 |
| Mathews, MB | 1 |
| Karn, J | 1 |
| Holland, B | 1 |
| Park, MH | 1 |
| Pe'ery, T | 1 |
| Palumbo, PE | 1 |
| Hanauske-Abel, HM | 1 |
| Georgiou, NA | 1 |
| van der Bruggen, T | 1 |
| Oudshoorn, M | 1 |
| Hider, RC | 1 |
| Marx, JJ | 1 |
| van Asbeck, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind, Placebo-controlled, Dose-escalating, Multiple Dose Study, Investigating the Safety, Antiretroviral Activity, Tolerability and Pharmacokinetic Profile of Deferiprone When Administered in Healthy Volunteers and Asymptomatic HIV Infected Subj[NCT02191657] | Phase 1 | 26 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for deferiprone and HIV Coinfection
| Article | Year |
|---|---|
Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Apoptosis; Cell Line; Cells, Cultured; Deferiprone; Dose-Respons | 2016 |
1 other study available for deferiprone and HIV Coinfection
| Article | Year |
|---|---|
Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis.
Topics: Apoptosis; Caspase 3; Caspases; Cell Division; Deferiprone; HIV Infections; HIV-1; Humans; Iron Chel | 2002 |